Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 10066 participants.

Also called NCT01327846

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 10,066 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01327846
  • EudraCT 2010-022970-14
Other papers using this trial's data
  • Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes Journal of the American College of Cardiology, 2018-05-29 DOI, PubMed 29544870
  • Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure Circulation, 2019-03-05 DOI, PubMed 30586730
  • Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease The New England journal of medicine, 2017-09-21 DOI, PubMed 28845751
  • Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Cancer prevention research (Philadelphia, Pa.), 2024-09-04 DOI, PubMed 38701435
  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial Lancet (London, England), 2017-10-21 DOI, PubMed 28855077
  • Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial Blood advances, 2023-12-26 DOI, PubMed 37934948, PMC10758744 In the PMC Open Access subset under CC BY-NC-ND.
  • Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS Hypertension (Dallas, Tex. : 1979), 2020-02 DOI, PubMed 31884854, PMC7055941 In the PMC Open Access subset under CC BY.
  • Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial Annals of internal medicine, 2020-04-21 DOI, PubMed 32203978, PMC7980674 PubMed links an erratum for this paper. Erratum: PMID 32658571 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial Annals of internal medicine, 2020-10-06 DOI, PubMed 32744862, PMC8503784 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial Journal of the American College of Cardiology, 2020-10-06 DOI, PubMed 33004131
  • Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease Journal of the American College of Cardiology, 2018-05-29 DOI, PubMed 29793629
  • Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) European heart journal, 2018-10-07 DOI, PubMed 30165610
  • Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial Annals of internal medicine, 2018-10-16 DOI, PubMed 30242335
  • Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis European heart journal, 2020-06-14 DOI, PubMed 31504417
  • TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial JAMA cardiology, 2022-05-01 DOI, PubMed 35385050, PMC8988022 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Guatemala, Hungary, Iceland, India, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway, Peru, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, Slovenia, South Africa, South Korea, Sweden, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01327846. Randomized; triple masking; primary purpose treatment. Start 2011-04-11 (actual); primary completion 2017-03-28 (actual). Results posted on 2020-01-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Acronym
CANTOS
Condition
Atherosclerosis
Intervention (Drug)
Canakinumab
Intervention (Drug)
Placebo
Intervention (Drug)
Standard of care
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01327846
Content hash
398f36d8870b264b0dae4afe23698ece5afd02016a5bc29905fc351ac4990461